Dow Down0.13% Nasdaq Up0.14%

Mylan N.V. (MYL)

-NasdaqGS
42.86 Up 0.18(0.42%) May 26, 4:00PM EDT
ProfileGet Profile for:
Mylan N.V.
Building 4
Trident Place
Hertfordshire, AL10 9UL
United Kingdom - Map
Phone: 44 1707 853000
Fax: 44 1707 261803
Website: http://www.mylan.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Drugs - Generic
Full Time Employees:35,000

Business Summary 

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream, or ointment forms, as well as active pharmaceutical ingredients (APIs). It is also involved in the development of APIs with non-infringing processes for internal use and to partner with manufacturers; and manufacture and sale of injectable products in antineoplastics, anti-infectives, anesthesia/pain management, and cardiovascular therapeutic areas. In addition, the company produces finished dosage form and oral solid dose products; and offers antiretroviral therapies to third parties. Further, it manufactures and sells branded specialty injectable and nebulized products comprising EpiPen Auto-Injector to treat severe allergic reactions; Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients; and ULTIVA, an analgesic agent used during the induction and maintenance of general anesthesia for inpatient and outpatient procedures. It sells generic pharmaceutical products to proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies; and specialty pharmaceuticals to pharmaceutical wholesalers and distributors, pharmacies, and healthcare institutions. Mylan N.V. has a collaboration agreement with Momenta Pharmaceuticals, Inc. to develop, manufacture, and commercialize Momenta Pharmaceuticals, Inc.’s biosimilar candidates. The company was formerly known as New Moon B.V. Mylan N.V. was founded in 1961 and is based in Hertfordshire, the United Kingdom.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Mylan N.V.

Corporate Governance 
Mylan N.V.’s ISS Governance QuickScore as of May 1, 2016 is 10. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 5; Compensation: 10.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Mr. Robert J. Coury , 55
Exec. Chairman and Chairman of Exec. Committee
10.02M34.01M
Ms. Heather Bresch , 47
Chief Exec. Officer, Exec. Director and Member of Science & Technology Committee
11.66M16.17M
Mr. Rajiv Malik , 55
Pres, Exec. Director and Member of Science & Technology Committee
14.93M11.18M
Mr. Anthony Mauro , 43
Chief Commercial Officer and Pres of North America
3.29M951.00K
Mr. Paul Campbell ,
Chief Accounting Officer, Sr. VP and Corp. Controller
N/AN/A
Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders